Abstract
A range of prospective studies have proven high efficacy of omega3-polyunsaturated fatty acids (omega3-FA, cod-liver oil (CLO)) in secondary prophylaxis of atherosclerosis and its complications. Monotherapy with CLO or its combination with statines in natients with hypertriglyceridemia substantially lowers triglyceride level. Due to their anti-inflammatory properties, including the capability of prostaglandin production reduction, clinical application of omega3-FA is indicated in high risk of preterm delivery, and in patients with rheumatoid arthritis. In the latter CLO application allows reduction of the dose of nonsteroidal anti-inflammatory drugs, and improves chief clinical symptoms (reduces pain and morning joint stiffness.)
Publication types
-
Comparative Study
-
English Abstract
-
Review
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
-
Arthritis, Rheumatoid / diet therapy
-
Arthritis, Rheumatoid / drug therapy
-
Cardiovascular Diseases / diet therapy
-
Cardiovascular Diseases / drug therapy
-
Cardiovascular Diseases / prevention & control
-
Cod Liver Oil / therapeutic use*
-
Coronary Disease / diet therapy
-
Coronary Disease / drug therapy
-
Dietary Supplements
-
Drug Therapy, Combination
-
Fatty Acids, Omega-3 / administration & dosage
-
Fatty Acids, Omega-3 / therapeutic use*
-
Female
-
Humans
-
Hypertriglyceridemia / drug therapy
-
Hypertriglyceridemia / prevention & control
-
Hypolipidemic Agents / administration & dosage
-
Hypolipidemic Agents / therapeutic use
-
Male
-
Middle Aged
-
Obstetric Labor, Premature / drug therapy
-
Obstetric Labor, Premature / prevention & control
-
Pregnancy
-
Prospective Studies
-
Randomized Controlled Trials as Topic
-
Triglycerides / blood
Substances
-
Anti-Inflammatory Agents, Non-Steroidal
-
Fatty Acids, Omega-3
-
Hypolipidemic Agents
-
Triglycerides
-
Cod Liver Oil